65,437 trials
Influenza
Primary: Number of Participants With Solicited Local and Systemic Reactions After Vaccination With Fluzone® 2004-2005 Pediatric Formulation — 3; 7; 0; 2 Participants
Influenza
Primary: Number of Participants Reporting Solicited Local and Systemic Reactions After Fluzone® Vaccination — 9; 6; 0; 2 Participants
Acellular Pertussis · Diphtheria · Tetanus
Primary: Anti-polyribosyl-ribitol-phosphate (PRP) Antibody Concentrations — 34.428; 132.075 μg/mL
Osteoporosis
Primary: Percentage Change From Baseline to 24 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD), Postmenopausal Women — 6.04; 1.65 percentage change in lumbar spine BMD…
Hypertension
Primary: The Percentage of Patients Achieving Target Sitting Blood Pressure of Less Than 130/85 — 34.0; 59.2 Percent of participants — p=0.0158
Lymphoma
Primary: Number of Participants With Response (Complete Response or Progressive Disease) — 2; 6 Participants
Menorrhagia
Primary: HRQoL (Health Related Quality of Life) — 0.08; 0.10 points on a scale
Macular Edema · Retinal Vein Occlusion
Primary: Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye — 53; 48; 38 Number of Participants
Schizophrenia
Primary: Change From Baseline to 2 Hours Post the First Intramuscular (IM) Injection in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) — -4.7; -4.6 units on a…
Macular Edema · Retinal Vein Occlusion
Primary: Cumulative Response Rate of 15 or More Letter Improvement — 0.101; 0.092; 0.045; 0.258 Kaplan-Meier Estimate
Healthy
Primary: Bioequivalence Based on Cmax for Amoxicillin — 10970.75; 10867.32 ng/mL
Influenza
Primary: Hemagglutination Inhibition (HI) Antibody Titer — 13.6; 11.6; 165.5; 68.2 titer
Healthy Children
Primary: Evaluation Tool of Children's Handwriting — 96 percent of legible letters — p=.27
Heart Failure
Primary: Safety (Subjects Without a Model 4196 Lead Related Complication) — 168 participants
Multiple Sclerosis, Relapsing-Remitting
Primary: Probability of Participants With Sustained Accumulation of Disability (SAD) — 0.27; 0.08; 0.09; 0.09 probability of participants with SAD — p=0.0006